Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
| ▸ | GNPAT | O15228 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GGH | Q92820 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156556 | 1.00 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL928640 | 0.88 | GNPAT (0.47) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL14310838 | 0.88 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL8861039 | 0.86 | FOLH1 (0.65) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL8861043 | 0.86 | FOLH1 (0.65) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL6270974 | 0.86 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL1533825 | 0.86 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL18106098 | 0.85 | MMP12 (0.47) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL6576395 | 0.85 | KMT2A (0.47) | FOLH1NAALAD2RIMKLAGNPATNOD1 | |
| SCHEMBL9752284 | 0.85 | GNPAT (0.62) | FOLH1NAALAD2RIMKLAGNPATNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239939-A1 | Combinations for introducing nucleic acids into cells | PLANK CHRISTIAN | 2009-09-24 | — | — | US | disclosed |
| EP-1198489-B1 | COMBINATIONS FOR INTRODUCING NUCLEIC ACIDS INTO CELLS | PLANK CHRISTIAN (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030026840-A1 | Combinations for introducing nucleic acids into cells | PLANK CHRISTIAN (DE) | 2003-02-06 | — | — | US | disclosed |
| EP-1208133-A1 | COPOLYMERS FOR THE TRANSFER OF NUCLEIC ACIDS TO THE CELL | Plank, Christian (DE) | 2002-05-29 | — | — | EP | disclosed |
| EP-1198489-A1 | COMBINATIONS FOR INTRODUCING NUCLEIC ACIDS INTO CELLS | Plank, Christian (DE) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001000709-A1 | COPOLYMERS FOR THE TRANSFER OF NUCLEIC ACIDS TO THE CELL | PLANK CHRISTIAN (DE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000708-A1 | COMBINATIONS FOR INTRODUCING NUCLEIC ACIDS INTO CELLS | PLANK CHRISTIAN (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-1063254-A1 | Copolymers for the transport of nucleic acids in the cell | Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung (DE) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030026840-A1 | Combinations for introducing nucleic acids into cells | POLRMT, RNASE1, POLI | FOLH1 375/4885NAALAD2 2373/4885RIMKLA 3618/4885 |
| US-20090239939-A1 | Combinations for introducing nucleic acids into cells | POLRMT, RNASE1, POLI | FOLH1 375/4885NAALAD2 2373/4885RIMKLA 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.